ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023
2023年11月8日 - 2:15AM
ImmuCell Corporation (Nasdaq: ICCC)
(“ImmuCell” or the “Company”), a growing animal health company that
develops, manufactures and markets scientifically proven and
practical products that improve the health and productivity of
dairy and beef cattle, expects to report unaudited financial
results for the quarter ended September 30, 2023 after the market
closes on Monday, November 13, 2023.
The Company expects to file its Quarterly Report on Form 10-Q
after the market closes on Monday, November 13, 2023. The Company
anticipates no change to the preliminary sales results for the
third quarter of 2023 that were disclosed on October 5, 2023.
The Company has scheduled a conference call the next morning,
Tuesday, November 14, 2023, at 9:00 AM ET to review its third
quarter financial results. Interested parties can access the
conference call by dialing (844) 855-9502 (toll free) or (412)
317-5499 (international) at 9:00 AM ET. A teleconference replay of
the call will be available until November 21, 2023 at (877)
344-7529 (toll free) or (412) 317-0088 (international), utilizing
replay access code #5077962.
Investors are encouraged to review the Company’s updated
Corporate Presentation slide deck that provides an overview of the
Company’s business which can be accessed under the “Investors” tab
of the Company’s website at www.immucell.com, or by request to the
Company, after the market closes on Monday, November 13, 2023.
About ImmuCell:ImmuCell Corporation's
(Nasdaq: ICCC) purpose is to create scientifically
proven and practical products that improve the health and
productivity of dairy and beef calves. ImmuCell manufactures
and markets First Defense®, providing
Immediate Immunity™ to newborn dairy and beef
calves, and is in the late stages of developing
Re-Tain®, a novel treatment for subclinical
mastitis in dairy cows with a no milk discard claim that provides
an alternative to traditional antibiotics. Press releases and other
information about the Company are available at:
http://www.immucell.com.
Contacts: |
Michael F.
Brigham, President and CEO |
|
ImmuCell Corporation |
|
(207) 878-2770 |
|
|
|
Joe Diaz, Robert Blum and Joe Dorame |
|
Lytham Partners, LLC |
|
(602) 889-9700 |
|
iccc@lythampartners.com |
ImmuCell (NASDAQ:ICCC)
過去 株価チャート
から 4 2024 まで 5 2024
ImmuCell (NASDAQ:ICCC)
過去 株価チャート
から 5 2023 まで 5 2024